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Background: Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by
life-threatening metabolic crises during general anesthesia. Classical triggering substances are volatile anesthetics
and succinylcholine (SCh). The molecular basis of MH is excessive release of Ca2+ in skeletal muscle principally by a
mutated ryanodine receptor type 1 (RyR1). To identify factors explaining the variable phenotypic presentation and
complex pathomechanism, we analyzed proven MH events in terms of clinical course, muscle contracture, genetic
factors and pharmocological triggers.
Methods: In a multi-centre study including seven European MH units, patients with a history of a clinical MH
episode confirmed by susceptible (MHS) or equivocal (MHE) in vitro contracture tests (IVCT) were investigated. A
test result is considered to be MHE if the muscle specimens develop pathological contractures in response to only
one of the two test substances, halothane or caffeine. Crises were evaluated using a clinical grading scale (CGS),
results of IVCT and genetic screening. The effects of SCh and volatile anesthetics on Ca2+ release from sarcoplasmic
reticulum (SR) were studied in vitro.
Results: A total of 200 patients met the inclusion criteria. Two MH crises (1%) were triggered by SCh (1 MHS, 1
MHE), 18% by volatile anesthetics and 81% by a combination of both. Patients were 70% male and 50% were
younger than 12 years old. Overall, CGS was in accord with IVCT results. Crises triggered by enflurane had a
significantly higher CGS compared to halothane, isoflurane and sevoflurane. Of the 200 patients, 103 carried RyR1
variants, of which 14 were novel. CGS varied depending on the location of the mutation within the RyR1 gene. In
contrast to volatile anesthetics, SCh did not evoke Ca2+ release from isolated rat SR vesicles.
Conclusions: An MH event could depend on patient-related risk factors such as male gender, young age and
causative RyR1 mutations as well as on the use of drugs lowering the threshold of myoplasmic Ca2+ release. SCh
might act as an accelerant by promoting unspecific Ca2+ influx via the sarcolemma and indirect RyR1 activation.
Most MH crises develop in response to the combined administration of SCh and volatile anesthetics.
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Malignant hyperthermia (MH) is a rare autosomal domin-
ant pharmacogenetic muscle disorder. The genetic inci-
dence is thought to be between 1:3,000 and 1:8,500 [1].
Predisposed individuals are at risk of developing a severe
drug-induced hyper-metabolic state resulting from altered
Ca2+ turnover in the skeletal muscle. Volatile anesthetics
and succinylcholine (SCh) are the classical triggering
agents. The principal clinical symptoms are hypercapnia,
acidosis, generalized muscle rigidity, cardiac arrhythmia
and high temperature [1]. These clinical symptoms are
used within a clinical grading scale (GCS) to predict the
probability of whether a clinical event might be an MH
crisis [2].
In skeletal muscle, the primary mode of Ca2+ release is
through direct protein-protein interaction between the volt-
age sensor of the t-tubular membrane, the dihydropyridine
-sensitive L-type Ca2+-channel CaV1.1 (DHPR) and the rya-
nodine receptor subtype 1 (RyR1), the Ca2+ release channel
of the sarcoplasmic reticulum (SR) (Figure 1A). The RyR1
is identified as a key element in the pathophysiology of MH
[3,4]. Currently more than 300 different variants of uncer-
tain significance in the gene coding for RyR1 have been de-
tected, however until now only 31 RyR1 mutations have
been proven to be causative for MH according to the
criteria of the European Malignant Hyperthermia Group
(see www.emhg.org). In very rare cases, a defect in the α1-
subunit of the DHPR has been reported [5], yet in up to
40% of the MHS families no mutations in either of the two
genes could be identified [6,7]. The genetic penetrance is
not fully understood because acute MH episodes are more
common in males and children [8].
Muscle of individuals with a RyR1 mutation exhibits an
increased sensitivity to volatile anesthetics: in vitro, MH
muscle is more sensitive to halothane compared to other
volatile anesthetics [9-12], however clinical studies have
yielded inconsistent conclusions [13-15]. The MH diagnos-
tic in vitro contracture test (IVCT) measures abnormally
strong contractures as a surrogate marker for halothane or
caffeine induced Ca2+ release from the SR [16]. MH suscep-
tibility is a clearly autosomal dominant in vitro. The
depolarizing muscle relaxant succinylcholine (SCh)
pharmacologically activates the nicotinergic acetylcho-
line receptor (nAChR) which acts as a nonspecific cation
channel resulting in a local long-lasting inward current
and corresponding depolarization of the cell membrane.
Since the nAChR is permeable to Ca2+, in addition to the
depolarisation the entry of Ca2+ may indicate the under-
lying mechanism of action of SCh in the pathogenesis of
MH. Acute crises triggered by SCh may be caused either
by a direct influx of extracellular Ca2+ via the nAChR, by
transient depolarization of the voltage-gated DHPR or by
unspecific Ca2+ influx such as store-operated Ca2+ entry
and Ca2+ entry coupled with excitation [17].In vitro studies could not show that SCh alone induces
pathological contractures in MH muscle strips although
it did enhance the effect of halothane [18] and caffeine
[19]. In vivo models are inconsistent with the in vitro
findings: Harrison showed that MH pigs developed an
increase in body temperature and muscle rigidity after
administration of SCh alone [20] and in a recently devel-
oped micro-dialysis pig model, halothane and not SCh
induced a hyper-metabolic reaction [21]. Using 284 sus-
pected clinical MH cases, Dexter et al. demonstrated an
increased risk of MH when SCh is used in combination
with volatile anesthetics while SCh alone was only rarely
seen as a trigger [22]. Additionally, pharmacological SCh
formulations used to contain the preservative 4-chloro-
m-cresol (4-CmC) which has been identified as a potent
RyR1 agonist [23]. It was subsequently removed from
SCh formulations in the 1980s [24].
The pathophysiology and variability of the clinical course
of MH is not fully understood. A genetic approach is com-
promised due to numerous mutations of unclear causality,
epigenetic factors and the involvement of at least two dif-
ferent Ca2+ conducting proteins. Functional testing (e.g.
IVCT, Ca2+ release experiments) can only clarify partial as-
pects of the pathomechanism of MH. The goal of this
study is thus to characterize a large cohort of proven clin-
ical MH events by comparing CGS with functional effects
on excised muscle bundles (IVCT) and genetic factors. We
were also interested in the MH specific differences in the
in vitro and in vivo characteristics of the classical MH trig-
gers, i.e. SCh and volatile anesthetics, as these drugs act on
different pharmacological pathways.
Methods
Multi-centre evaluation
Seven European MH test units participated in this multi-
centre study: Basel, Switzerland; Nijmegen, Netherlands;
Naples, Italy; Leipzig, Germany; Padua, Italy; Ulm, Germany;
and Würzburg, Germany. Patients were included if they suf-
fered from a clinical MH episode confirmed by a positive or
an equivocal IVCT. These experimental investigations were
part of the routine diagnostic algorithm used in MH suscep-
tibility testing. Written informed consent was obtained from
the patients or their legal guardians. Data collected included
age, gender, year of crisis, clinical grading scale (CGS), infor-
mation of the administration of MH trigger substances and
results of the IVCT. All data sets were imported into a
multi-centre database.
Clinical grading scale
The MH episodes of the patients were analyzed by cal-
culating the clinical grading scales (CGS) according to
Larach et al. 1994 [2]. In brief, the CGS is a scoring sys-
tem estimating the likelihood of an MH event using sev-
eral indicators: masseter spasms or generalized muscle
Figure 1 (See legend on next page.)
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Figure 1 Effects of MH triggers on Ca2+ release. A: Uncontrolled myoplasmic Ca2+ release is the key to malignant hyperthermia. The most
prominent cytosolic Ca2+ elevation results from the freeing of stored sarcoplasmic Ca2+ mediated by ryanodine receptor type 1 (RyR1). While
volatile anesthetics stimulate Ca2+ release via RyR1, succinylcholine acts indirectly by activating the nicotinergic acetylcholine receptor (nAChR), a
nonspecific cation channel, resulting in continuous local depolarisation. The depolarization can trigger propagated action potentials and will
further activate the dihydropyridine receptors (DHPR, CaV1.1) leading to the gating of both Ca
2+ release from the SR via RyR1 and L-type Ca2+
current from the extracellular space. B: Heavy SR from rat muscle was maximally preloaded with Ca2+ before testing the potential Ca2+ releasing
agonists halothane, isoflurane, enflurane and succinylcholine. The resulting Ca2+ release is via the RyR1 channel. Halothane, isoflurane and enflurane
induced Ca2+ release from the SR vesicles but succinylcholine had no detectable effect. Results are expressed as mean ± standard error from six
separate SR specimens. Of the three anesthetics tested, halothane showed the greatest potency and efficacy.* C: Succinylcholine (SCh) significantly
increases halothane induced contractures in malignant hyperthermia susceptible individuals. However, SCh alone does not lead to the development of
pathological contractures in MHN or MHS individuals*. *Part of the data from Figure 1B and C was published in Klingler et al. in 2005 [25].
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kinase (CK) or maximum serum myoglobin levels (process
II: muscle breakdown), maximum PaCO2 (process III: re-
spiratory acidosis), maximum temperature (process IV:
temperature increase), tachycardia or ventricular arrhythmia
(process V: cardiac involvement), negative base excess
(BE), arterial acidosis, and rapid reversal of MH signs
after IV dantrolene (other indicators). The highest score
of the processes noted are added together. The resulting
raw scores are assigned as MH ranks which helps to
predict the likelihood of an acute MH crisis: MH rank
1: “almost never”, MH rank 2: “unlikely”, MH rank 3:
“somewhat less than likely”, MH rank 4: “somewhat
greater than likely”, MH rank 5: “very likely” and MH
rank 6: “almost certain”. Only datasets were included in
which all necessary parameters for the calculation of
CGS were measured and available.
In vitro contracture test
Biopsies were taken from the vastus medialis or lateralis of
the quadriceps muscle under regional anesthesia or trigger-
free general anesthesia. The muscle specimens were used
to perform IVCTs using the regularly revised protocol of
the European Malignant Hyperthermia Group (EMHG)
[16]. This test is used to determine the sensitivity of the
skeletal muscle to caffeine and halothane which in turn al-
lows assessment of the predisposition to MH. The viable
specimens were kept at 37°C, pH 7.4 in Krebs-Ringer solu-
tion (mmol L-1: NaCl 118.1; KCl 3.4; CaCl2 2.5; MgSO4 0.8;
KH2PO4 1.2; NaHCO3 25.0; glucose 11.1) and dissected
into individual strips 15 mm to 25 mm length, 2 mm to
3 mm in width and 100 mg to 300 mg in weight. Muscle
strips with twitch amplitudes greater than 10 mN to supra-
maximal electrical stimulation (pulse frequency of 0.2 Hz;
pulse width of 1 ms), or a contracture of ≥ 50 mN in the
caffeine test in response to 32 mmol L-1 caffeine were con-
sidered viable. The force elicited was detected by a myo-
electrical transducer (e.g. the FT03 from Grass Instruments,
Quincy, MA). Pathological contractures were defined as
having a threshold of 2 mN occurring at concentrations of
2 mmol L-1 caffeine or less or 2% (v/v) (0.44 mmol L-1)
halothane or less. Individuals with pathological contracturesrelated to both caffeine and halothane were considered to
be MH susceptible (MHS); patients whose specimens de-
veloped pathological contractures to only one test drug
were considered to be MH equivocal (MHEc for caffeine
positive, MHEh for halothane positive), and if no patho-
logical contractures occurred at 2 mmol L-1 caffeine and
2% (v/v) halothane the patient was classified as MH nega-
tive (MHN). Surplus tissue from muscle biopsy specimens
of the Ulm MH unit was used in further analysis with the
approval of the local ethics committee (Ethics Committee
of Ulm University). The contracture forces following a
pharmacological challenge with 500 μmol SCh, 2% (v/v)
halothane, and the combination of both substances was
studied. Halothane was purchased from Zeneca (Planck-
stadt, Germany), and preservative-free SCh was purchased
from Curamed Pharma (Karlsruhe, Germany). Further de-
tails are provided in Klingler et al. 2005 [25].
Genetic screening
Blood samples of the patients were genetically screened
for RyR1 mutations of all 106 RYR1 exons and additionally
for known mutations of CACNA1S. The CACNA1S gene
encodes for the α1-subunit of the L-type Ca2+ channel
CaV1.1. Briefly described, blood cells were haemolysed and
then DNA was extracted and amplified by polymerase
chain reaction for further analysis. Details of the method
are described in Zullo et al. 2009 [26]. Three different pre-
diction algorithms were used to estimate a possible impact
of novel amino acid substitutions on structure and func-
tion of RyR1: SIFT (http://sift.jcvi.org/), Mutation taster
(http://www.mutationtaster.org/), and Polyphen2 (http://
genetics.bwh.harvard.edu/pph2/).
Ca2+ Release in isolated SR
Heavy SR was prepared from hind limb muscles of rats as
previously described [25,27]. Ca2+ release was measured by
spectrophotometry using a HP 8452A diode-array spectro-
photometer operating in dual wavelength mode at 710 nm
and 790 nm at 37°C with constant magnetic cuvette stir-
ring. Isolated SR was incubated with the Ca2+ chelometric
dye antipyralazo III in a total volume of 2 ml in a ground
glass-stoppered glass cuvette using a medium containing
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dium pyrophosphate, 1 mmol L-1 MgATP, 5 mmol L-1 cre-
atine phosphate, 20 μg/ml CK and 250 mmol L-1
antipyralazo III at pH 7.0. Ca2+ flux was monitored con-
tinuously over time, and when the SR was maximally
loaded with Ca2+ potential releasing agents were added at
varying concentrations to establish whether Ca2+ release
occurred. Succinylcholine, halothane, isoflurane and en-
flurane were added to the cuvette from concentrated stock
solutions made up in pure ethanol using a gas-tight
micro-syringe. Controls showed that ethanol had no effect
at the concentrations used. SR protein concentration was
measured as previously reported [25,27]. Anesthetic con-
centrations in the cuvette reaction medium were analyzed
using electron capture gas chromatography. The three an-
esthetics were first purified by distillation [27].
Statistical analysis
Results are presented as a mean with standard deviation.
Discrete data are also provided as median and interquar-
tile range (25% to 75%), black horizontal lines within the
boxes show median values, whiskers indicate ranges and
white squares represent mean values. Differences between
the groups were assessed using the non-parametric
Mann–Whitney U-test (also known as Wilcoxon rank-
sum test or Mann–Whitney-Wilcoxon) and results were
interpreted as significant if p < 0.05.
Results
Differing in vitro effects of volatile anaesthetics
and succinylcholine
In a first set of experiments, we investigated different sub-
cellular action sites within muscle fibres (Figure 1A). We
analysed isolated SR-vesicles and found that volatile anes-
thetics stimulate SR mediated Ca2+ release: Isolated heavy
SR of rat muscle strips revealed a significant increase in
Ca2+ after administration of halothane, isoflurane and en-
flurane. In contrast to the effects observed with volatile
anesthetics, SCh did not affect Ca2+ release from isolated SR
vesicles at concentrations of up to 1 mmol L-1 (Figure 1B).
Myographic recordings show that preservative-free SCh
at concentrations of up to 1 mmol L-1 does not evokeTable 1 Multicenter evaluation of triggering potency
Trigger No. of patients
MHS MHE
Vol. anesthetics 30 6
SCh 1 1
Vol. anesthetics + SCh 134 28
Total 165 35
The vast majority of the cases were triggered by the combination of volatile anesth
by SCh alone, along with one MHE case. The clinical grading scale according to Lar
MH. Data are shown as median and interquartile range (25% - 75%).contractures in isolated muscle bundles. There was however
a significant contracture increase when SCh was combined
with halothane or caffeine (Figure 1C).
Multi-centre evaluation
Seven European MH test units participated in this multi-
centre evaluation. The data set included 263 patients. In
total 63 of them had to be excluded from the study: 60 of
these were due to incomplete initial clinical documenta-
tion, three of them because of possibly interfering co-
morbid factors: one being an intensive care patient with
malaria and pneumonia, one being a polytrauma patient
with hereditary sensorimotor neuropathy type 1 (Charcot-
Marie-Tooth disease) and one being a King-Denborough
patient with a non-anesthetic event. The remaining 200
cases were included – 165 of them MHS and 35 MHE.
These crises happened during the time period from 1972
to 2010; patients were subsequently transferred to one of
the investigation units of this multi-centre study for diag-
nosis. In five patients central cores were identified histolog-
ically. All of them carried RyR1 mutations of unknown
causality (p.R4735E, p.I2453T, p.I4138T, p.D60Y, p.E342K).
The histological examination yielded non classifiable
core like lesions in another patient. She carried the
RyR1 mutation p.R44C and suffered a severe clinical
crisis (CGS = 78 points).
There was only one conclusive MHS patient whose MH
crisis was triggered by SCh in the absence of volatile anes-
thetics. This 13 years old boy developed a masseter spasm
and generalized muscle rigidity after induction with thio-
pental and intubation with SCh during ENT surgery; dan-
trolene was not given. He later showed a peak creatine
kinase of 17,768 U/L. The calculated CGS was 15 points
(rank 3: “somewhat less than likely”). The IVCT showed
an abnormal reaction (MHS) and genetic analysis revealed
a causative RyR1 mutation (p.R614C). Similarly one MHE
patient was triggered by SCh alone: This 10 years old boy
underwent emergency surgery because of testicular tor-
sion. After application of SCh without pre-curarization
clinical signs compatible with MH were masseter spasm
and increased body temperature (40°C) (CGS = 25 points,
rank 4 “somewhat greater than likely”). The IVCT wasClinical grading scale
(raw score)
MHS MHE
40.5 (28.5 - 61.0) 34.0 (30.8 - 41.0)
15 25
43.0 (30.0 - 55.0) 33.0 (15.0 - 40.0)
43.0 (30.0 - 55.8) 33.0 (19.0 - 40.0)
etics and succinylcholine (SCh). Remarkable only one MHS case was triggered
ach et al. 1994 classifies a raw score of more than 35 as very likely to be clinical
Figure 2 Clinical effects of volatile anesthetics. A: Box and whisker plots showing clinical grading scales (CGS) of 200 malignant hyperthermia
susceptible (MHS, n = 165) or equivocal (MHE, n = 35) patients depending on the anesthetic agent used. Enflurane developed a significantly higher
CGS compared to halothane, isoflurane and sevoflurane. B: CGS depending on the in vitro contracture test results: malignant hyperthermia susceptible
(MHS), malignant hyperthermia equivocal halothane positive (MHEh) and caffeine positive (MHEc). A Mann–Whitney U-test was performed and yielded
significant differences between MHS vs. MHEh, i.e. MHS vs. (MHEh +MHEc). C: Patients in this study with clinical crises that resulted in high MH Ranks
(5 and 6) developed greater halothane and caffeine contractures than patients with lower MH Ranks (3 and 4). Asterisks (*, **) indicate significant
differences. Columns represent mean ± standard error of the mean and black horizontal lines within the columns show median values.
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Figure 3 Age and gender preponderance. Age and gender of
200 MH patients at the time of the clinical MH-episode.
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detected.
In the majority (MHS = 81%, MHE = 80%) both volatile
anesthetics and SCh were administered. In the other cases
(MHS = 18%, MHE = 17%) patients had received volatile
anesthetics alone (Table 1). A Mann–Whitney U-test was
performed which showed no significant difference in the
raw score of CGS between patients who received volatile
anesthetics alone and those who received volatile anes-
thetics plus SCh. The enflurane subgroup showed a sig-
nificantly higher CGS compared to halothane, isoflurane
and sevoflurane (Figure 2A).The age of the halothane
group (10.5 ± 10.4) was significantly younger compared to
the age of those receiving desflurane (40.5 ± 18.7), enflur-
ane (19.7 ± 11.1), isoflurane (27.2 ± 15.6) and sevoflurane
(20.5 ± 12.8). Patients classified as MHS showed a signifi-
cantly higher CGS (43.8 ± 19.6) compared to those tested
MHE (32.3 ± 14.5) (Figure 2B), even though the distribu-
tion of halothane and enflurane cases were similar in both
subgroups (halothane 6.07 vs. enflurane 6.33). The IVCT
and CGS results showed consistent results: MH ranks 5
and 6 developed significantly higher contractures and sig-
nificantly lower thresholds compared to MH ranks 3 and
4 (Figure 2C). Half of the patients (50%) were younger
than 12 years old at the time of crises and males (70%)
were more often affected than females (30%) (Figure 3),
however the CGS and the IVCT parameters did not differ
significantly between males and females or adults and
children.
Genetic evaluation
The overall RyR1 variant detection rate was 52%; 51 differ-
ent RyR1 mutations were detected in 101 patients (Table 2).
Four patients carried two RyR1 mutations (Table 3). Over-
all 14 new RyR1 variants are described in this study. Re-
sults of SIFT, Mutation taster and Polyphen2 analysis is
shown in Tables 2 and 3. Two patients carried RyR1 poly-
morphisms: exon 15, c.1655G >A, p.R552Q (new variant,
personal communication with V. Sorrentino) and exon 38,
c.6178G > T, p.G2060C [6] which occurs in 6% of the
European population according to GeneCards. One MHS
patient showed a nonsense mutation in exon 103
(c.14833C > T, p.R4945X, novel variant, K. Jurkat-Rott).
Stop codon mutations like R4945X have been identified in
several MH families but they never segregated with the
MHS status in the given family. One patient showed a
CaV1.1 mutation (exon 4, c.520C > T, p.R174W); further
statistical analysis was therefore not possible. Four patients
did not give permission for genetic screening and there-
fore had to be excluded from genetic analyses. Most of the
RyR1 mutations were found inside the “hot spots” (MH/
CCD regions 1, 2 and 3) (Figure 4A). The halothane and
caffeine contractures were both significantly higher if the
mutation was found in one of these hot spots. Consistently,the thresholds of both test substances were significantly
lower in hot spot mutations and these patients showed
higher raw scores in the CGS (Figure 4B,C).
Patients with causative RyR1 mutations (as defined by
EMHG) developed greater contractures, lower thresholds
and higher raw scores in the CGS compared to patients
with RyR1 mutations of unknown causality; however des-
pite obvious caffeine contractures, no significant differ-
ences were detected between patients with mutations of
unknown causality and patients without a RyR1 mutation
(Table 4). In 8 of 35 MHE patients, an RyR1 mutation has
been identified.
Discussion
Age and gender preponderance
The CGS was designed as an indicator for the likelihood
that a given anesthetic crisis is MH. However, if the
anesthetist recognized the crisis early and consequently
started treatment, the crisis might result in a deceptively
low CGS. There may be other factors (e.g. hormonal ef-
fects) that influence the risk of developing an acute MH
episode. Our result resembles in part the findings of
Islander et al. 2007 [8] and Green Larach et al. 2010 [52]:
children (50%) and males (70%) dominate the case num-
bers, although results of IVCT and CGS did not differ be-
tween males and females.
RyR1 mutations
At present there are more than 300 single nucleotide
polymorphisms of the RyR1 known, while only 31 vari-
ants are functionally characterized as MH causative
(www.emhg.org). The severity of IVCT varies between
individuals with different RYR1 mutations [53]. In this
study we confirm these findings and provide evidence
that the RYR1 variants also vary in the severity of the
clinical MH episodes: the clinical events were significantly
Table 2 Mutations of ryanodine receptor type 1
In vitro contracture test
Contracture Threshold
Exon Nucleotide Substitution No. of patients
in this study
2 vol%
halothane [mN]
2 mmoll-1
caffeine [mN]
Halothane
[vol%]
Caffeine
[mmoll-1]
Clinical
grading scale
Causative
mutation?
PolyPhen2
predictions
Sift
predictions
Mutation
Taster
predictions
Reference
2 c.130C>T p.R44C 1 12.0 10.8 0.5 1.0 78.0 No Tammaro et al.
2003 [28]
3 c.178G>T p.D60Y 1 13.0 4.5 1.0 2.0 30.0 No + + + This study,
V. Sorrentino
11 c.1021G>A p.G341R 3 14.3 ± 4.8 13.7± 3.1 0.8 ± 0.2 0.8 ± 0.5 54.3 ± 4.9 Yes Quane et al. 1994 [29]
11 c.1024G>A p.E342K 1 37.8 23.8 0.5 0.5 30.0 No + + + This study,
K. Jurkat-Rott
11 c.1100G>A p.R367Q 1 10.0 4.1 0.5 1.5 15.0 No Galli et al. 2006 [30]
12 c.1201C>T p.R401C 1 17.0 7.0 1.0 1.5 18.0 No Davis et al. 2002 [31]
12 c.1202G>A p.R401H 1 21.0 12.0 1.0 1.5 55.0 No Rüffert et al. 2002 [32]
15 c.1655G>A p.R552Q* 1 36.0 8.0 0.5 1.5 38.0 No + - + This study,
V. Sorrentino
17 c.1840C>T p.R614C 25 13.7 ± 8.9 10.5± 8.3 0.9 ± 0.5 1.3 ± 0.7 50.8 ± 22.3 Yes Gillard et al. 1992 [33]
17 c.1841G>T p.R614L 2 16.6 ± 2.6 8.3 ± 2.3 0.5 ± 0.0 1.0 ± 0.5 30.5 ± 2.5 Yes Quane et al. 1997 [34]
34 c.5011G>A p.A1671T 1 8.0 24.8 2.0 0.5 35.0 No + + - This study,
K. Jurkat-Rott
38 c.6178G>T p.G2060C* 1 16.4 8.0 0.5 1.0 88.0 No Robinson et al. 2006 [6]
39 c.6377G>A p.R2126Q 1 26.8 8.8 0.5 2.0 35.0 No Kraeva et al. 2011 [7]
39 c.6387C>G p.D2129E 1 10.0 11.0 2.0 1.0 45.0 No Rüffert et al. 2001 [35]
39 c.6488G>C p.R2163P 1 20.0 4.0 1.0 2.0 55.0 No Robinson et al.
2006 [6]
39 c.6502G>A p.V2168M 6 22.5 ± 7.1 12.3 ± 5.0 0.5 ± 0.0 1.1 ± 0.3 58.8 ± 20.5 Yes Manning et al.
1998 [36]
40 c.6599C>T p.A2200V 1 - 3.0 - 2.0 10.0 No Sambuughin et al.
2005 [37]
40 c.6617C>T p.T2206M 9 20.5 ± 10.7 10.4 ± 4.9 0.9 ± 0.4 1.0 ± 0.4 50.4 ± 16.2 Yes Manning et al.
1998 [36]
41 c.6710G>A p.C2237Y 1 6.0 6.0 0.5 1.0 38.0 No + + + This study,
M. Snoeck
43 c.7007G>A p.R2336H 4 12.8 ± 4.5 11.7 ± 6.1 0.8 ± 0.3 1.1 ± 0.2 47.3 ± 4.4 No Levano et al. 2009 [38]
43 c.7025A>G p.N2342S 1 3.0 0.0 2.0 4.0 30.0 No Marchant et al.
2004 [39]
44 c.7034G>C p.S2345T 1 32.0 24.0 0.5 1.0 28.0 No (+) - + This study,
V. Sorrentino
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Table 2 Mutations of ryanodine receptor type 1 (Continued)
44 c.7048G>A p.A2350T 1 22.0 9.0 1.0 1.0 55.0 Yes Sambuughin
et al. 2001 [40]
44 c.7076G>A p.R2359Q 1 3.0 4.0 2.0 2.0 15.0 No (+) - + This study, H. Rüffert
44 c.7085A>G p.E2362G 1 16.0 8.0 0.5 1.0 43.0 No Galli et al. 2006 [30]
44 c.7112A>G p.E2371G 1 16.0 10.0 1.0 1.5 91.0 No Zullo et al. 2009 [26]
44 c.7124G>C p.G2375A 2 19.5 ± 0.5 20.5 ± 1.5 0.5 ± 0.0 0.8 ± 0.3 59.5 ± 11.5 Yes Rüffert et al. 2002 [41]
45 c.7300G>A p.G2434R 5 24.3 ± 14.4 12.2 ± 8.2 0.7 ± 0.2 1.1 ± 0.6 57.4 ± 19.9 Yes Sambuugghin
et al. 2001 [42]
46 c.7354C>T p.R2452W 1 8.0 20.0 1.0 1.5 48.0 No Chamley et al. 2000 [43]
46 c.7358T>C p.I2453T 1 7.0 7.0 1.0 1.5 63.0 No Rüffert et al. 2002 [41]
46 c.7360C>T p.R2454C 1 9.2 6.0 0.5 1.0 28.0 Yes Brandt et al. 1999 [44]
46 c.7361G>A p.R2454H 3 15.3 ± 5.7 13.0 ± 6.5 0.8 ± 0.2 1.0 ± 0.4 48.0 ± 12.2 Yes Barone et al. 1999 [45]
46 c.7372C>T p.R2458C 2 7.3 ± 1.3 2.0 ± 1.0 1.0 ± 0.0 2.0 ± 0.0 41.5 ± 31.5 Yes Manning et al. 1998 [46]
71 c.10616G˃A p.R3539H 1 7.0 8.0 2.0 1.5 38.0 No Dekomien et al.
2005 [47]
85 c.11708G>A p.R3903Q 2 4.8 ± 0.2 2.5 ± 0.5 2.0 ± 0.0 2.0 ± 0.0 25.0 ± 5.0 No Galli et al. 2006 [30]
85 c.11723A>T p.N3908I 1 8.0 4.8 1.0 1.5 20.0 No + + + This study,
K. Jurkat-Rott
90 c.12398A>G p.E4133G 1 2.0 2.5 2.0 2.0 10.0 No + + + This study,
V. Sorrentino
90 c.12413T>C p.I4138T 1 11.0 15.0 1.0 1.0 25.0 No Robinson et al. 2006 [6]
90 c.12532G>A p.G4178S 1 32.0 8.0 0.5 1.5 38.0 No + + + This study,
V. Sorrentino
95 c.13990T>C p.C4664R 1 20.0 4.0 1.5 1.5 50.0 No Zullo et al. 2009 [26]
98 c.14204G>A p.R4735Q 1 7.0 5.0 1.0 1.5 50.0 No + - + This study, H. Rüffert
101 c.14545G>A p.V4849I 3 3.8 ± 3.1 3.3 ± 0.8 1.5 ± 0.5 2.0 ± 0.0 36.3 ± 8.5 No Jungbluth
et al. 2002 [48]
101 c.14627A>G p.K4876R 1 14.0 14.0 0.5 0.5 48.0 No Monnier et al. 2005
[49]
103 c.14833C>T p.R4945X 1 9.9 23.3 0.5 0.5 15.0 No na na + This study,
K. Jurkat-Rott
106 c.15059G>C p.W5020S 1 1.0 2.0 - 2.0 43.0 No + + + This study,
V. Sorrentino
Overview of all ryanodine receptor type 1 (RyR1) mutations that have been detected in this study. If more than one patient carried the same mutation results of in vitro contracture tests (IVCT) and clinical grading
scales are shown as mean ± standard deviation. Patients with double RyR1 mutations are listed separately. Novel variations (n = 13) are highlighted (bold). Polymorphisms (n = 2) are marked with asterisks (*).
Polyphen2: + = probably damaging, (+) = possibly damaging, - = benign, na = not applicable to truncations; Sift: + = deleterious, - = tolerated, na = not applicable to truncations; Mutation taster:
+ = disease-causing; - = polymorphism.
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Table 3 Double mutations of the ryanodine receptor type 1
In vitro contracture test
Contracture Threshold
No. of patients
in this study
Exon Nucleotide Substitution Causative
mutation?
PolyPhen2
predictions
Sift
predictions
Mutation taster
predictions
References 2 vol%
halothane [mN]
2 mmoll-1
caffeine [mN]
halothane
[vol%]
caffeine
[mmoll-1]
CGS
1 11 c.1100G>T p.R367L No + - + This study, T. Girard 20.0 4.5 1.0 1.5 48
65 c.9649T>C p.S3217P No Levano et al. 2009 [38]
1 8 c.677T>A p.M226K No Robinson et al. 2006 [6] 53.0 24.0 0.5 0.5 38
28 c.4024A>G p.S1342G No Levano et al. 2009 [39]
1 44 c.7085A>G p.E2362G No Galli et al. 2006 [30] 56.0 57.0 0.5 0.5 35
93 c.13513G>C p.D4505H No Groom et al. 2011 [50]
1 29 c.4178A>G p.K1393R No Vukcevic et al. 2010 [51] 15.0 12.0 0.5 1.5 35
98 c.14210G>A p.R4737Q No Monnier et al. 2005 [49]
In this study four patients carried a double mutation of the ryanodine receptor type 1 (RyR1). These patients had marked outcomes in the in vitro contracture tests but clinical grading scales were avarage (mean:
39.00 points). Due to the small number of cases a statistical analysis was not performed. Novel mutations (n = 1) are highlighted (bold). CGS = clinical grading scale.
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Figure 4 (See legend on next page.)
Klingler et al. Orphanet Journal of Rare Diseases 2014, 9:8 Page 11 of 15
http://www.ojrd.com/content/9/1/8
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Figure 4 Locations and effects of ryanodine receptor type 1 mutations. A: Amino acid (AS) sequence of the ryanodine receptor type 1
(RyR1) from the n-terminal end to the c-terminal end. Most of the mutations found in this study are located in one of the three hot spots: MH/
CCD region 1: AS 35 to 614; MH/CCD region 2: AS 2163 to 2458; MH/CCD region 3: AS 4664 to 5020. B: Clinical grading scale (mean) for each
RyR1 mutation in regard of the location of the patients mutation within the gene. C: Box plot showing clinical grading scales (CGS) depending
on the location of the ryanodine receptor type 1 mutation. Boxes delineate the inter-quartile range (25% to 75%), black horizontal lines within
the boxes show median values, whiskers indicate ranges and white squares represent mean values. Mann–Whitney U-test reveals significantly
higher CGS of MH/CCD region 1, 2 and 3 compared to other regions of the protein.
Klingler et al. Orphanet Journal of Rare Diseases 2014, 9:8 Page 12 of 15
http://www.ojrd.com/content/9/1/8more severe in patients suffering from mutations inside
MH/CCD regions 1, 2 and 3. SIFT, Mutation taster and
Polyphen2 were used to characterize the relevance of novel
RyR1 variants. All three prediction algorithms favour a
possible effect on the protein function for the amino
acid substitutions p.D60Y, p.E342K, p.C2237Y, p.N3908I,
p.E4133G, p.G4178S and p.W5020S. Therefore a causative
association to MH is likely. However, functional Ca2+ re-
lease experiments are needed to confirm gain of RyR1
function needed for MH susceptibility. Including the 14
novel RyR1 variants, 38 patients carried RyR1 mutations
that have not yet been functionally analyzed. Those vari-
ants of unknown causality did develop less severe MH cri-
ses compared to functional analyzed causative mutations.
Interestingly, mutations of unknown causality did not dif-
fer in the CGS compared to patients with wild-type RyR1.
The RyR1 mutation p.R4945X is unlikely to cause MH be-
cause it results in a non-functional protein product rather
than a gain-of-function as required for causative MH
Mutations.
Volatile anesthetics
In this study enflurane produced the highest CGS: the dif-
ferences compared to halothane, isoflurane and sevoflur-
ane were significant. However, this tendency was not
found in other studies [14,15] and might be biased by dif-
ferential handling of the crises such as the rapidness of
dantrolene administration. Most crises were triggered by
halothane. This might be influenced by the fact that halo-
thane has been in use over the longest time span. On the
other hand, patients in this study who received halothane
were significantly younger compared to those who re-
ceived other volatile anesthetics. At this point the patient’s
age can be considered to be confounding variable; evenTable 4 Effect of causative ryanodine receptor type 1 mutatio
Classification of
RyR1 mutation
Clinical
grading scale
Contracture
2 vol% halothane 2
Causative 51.10 ± 20.67* + 16.77 ± 9.84 + * 1
Unknown causality 38.08 ± 17.46* 11.69 ± 8.99* 8
None detected 37.55 ± 16.90+ 11.43 ± 10.90+ 7
Causative ryanodine receptor type 1 (RyR1) mutations yield greater contractures, lo
of 189 patients are shown as mean ± standard deviation, Mann–Whitney U test was
and cross (+). Despite caffeine contractures there were no significant differences be
double RyR1 mutations (n = 4) and CaV1.1 mutations (n = 1) are not included in thisthough the CGS did not differ between age groups. As a
result, the high number of halothane cases may not lead
to any conclusion regarding its relative triggering potency.
Still, in rat muscle halothane was significantly more likely
to cause RyR1 mediated Ca2+ release than enflurane. In
the literature, halothane is almost uniformly considered to
be the most potent MH trigger [9-13]. Nonetheless, using
the onset time of clinical symptoms Allen et al. did not
find significant differences between halothane and desflur-
ane when analyzing 365 unconfirmed crises from the
American MH registry [14], and similarly Hopkins did not
find significant differences between halothane and isoflur-
ane in 75 cases confirmed by a positive IVCT [15]. Further-
more the relative triggering potencies of the other volatile
anesthetics vary markedly in the above cited publications.
MH crises triggered by desflurane are described but
seem to happen rarely: for example during the years 1990
to 2005, only two such cases were referred to the UK MH
unit in Leeds [15]. In our study, we note four additional
desflurane crises (CGS raw score = 38.5 ± 12.0), each con-
firmed by an MHS result in the IVCT.
Succinylcholine
SCh activates the nAChR which depolarizes the muscle
membrane by acting as an ion channel permeable to K+,
Na+ and also Ca2+ [54]. The depolarisation triggers propa-
gated action potentials initially; these rapidly cease due
to the refractoriness. The remaining nAChR-mediated
depolarization spreads some distance electrically along the
fibre axis depending on the fibre’s cable properties. In the
t-tubules, it activates the DHPRs (CaV1.1) which may lead
to both entry of Ca2+ from the extracellular space and
(through mechanical coupling) opening of the RyR1 along
with Ca2+ release [55]. Whereas SCh action activates then
(mN) Threshold
mmol l-1 caffeine halothane (vol%) Caffeine (mmol l-1)
0.94 ± 7.24* 0.81 ± 0.44 + * 1.14 ± 0.63 + *
.73 ± 6.90* 1.10 ± 0.58* 1.50 ± 0.64*
.52 ± 10.02* 1.30 ± 0.83+ 2.35 ± 7.70+
wer thresholds and higher raw score in the clinical grading scale (CGS). Results
performed and significant differences (p < 0.05.) were marked with asterisk (*)
tween unknown causality vs. none detected. RyR1 polymorphisms (n = 2),
table.
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thetics cross the membrane and stimulate RyR1. In rat
muscle volatile anesthetics were able to induce RyR1 me-
diated Ca2+ release, but not SCh [25]. Surprisingly we did
not observe differences in the CGS of crises triggered by a
SCh only versus SCh and volatile anesthetics. However
the onset of MH crises was significantly faster when vola-
tile anesthetics were combined with SCh [56]. The fact
that we observed a SCh associated clinical crisis in the ab-
sence of volatile anesthetics does not prove MH triggering
because undetected genetic variations or conditions
explaining SCh hypersensitivity cannot be excluded.
Still, a recent study revealed that in more than 50% of the
suspected MH crises in North America usage of SCh was
recorded, while SCh was present in only 5% to 10% of all
anesthetic records. Although this study was investigating
unconfirmed crises only, the authors were able to demon-
strate that the usage of SCh enhances the risk of an MH
crisis developing when volatile anesthetics are given. [22].
Conclusions
The consistent results of IVCT and CGS show that there
must be patient-associated factors that determine the se-
verity of an MH reaction. Conversely clinical penetration
is variable as the same patient can undergo anesthesia with
triggering agents and not develop clinical signs of MH.
In this study, a large group of patients (n = 38) have
uncharacterized RyR1 mutations. Statistical analysis showed
that these patients did develop less severe contractures and
higher thresholds in the IVCT as well as lower raw score in
the CGS. We conclude that this group of RyR1 mutations
of unknown causality consists of both causative mutations
still lacking proof of causality and non-causative RyR1 vari-
ants (polymorphisms). Also the genetic data show that the
severity of MH varies depending on the location of the
RyR1 mutation within the protein. The clinical observations
of this multi-centre study indicate that the nAChR pathway
might have the weakest potential in triggering an acute MH
crisis. The data show that nearly all proven MH episodes
were triggered by a combination of volatile anesthetics and
SCh (81%) or volatile anesthetics only (18%). Notably the
SCh only case in this study happened to a patient who
showed all patient related risk factors: he was male,
young (12 years old) and carried the causative RyR1
mutation p.R614C located within MH/CCD region 2.
He developed a CGS of 15 points, which represents a
less severe event. An anesthetist should be aware of
possible MH reactions to SCh in clinical practice and
moreover should know that the combination of volatile
anesthetics and SCh in particular is dangerous in pre-
disposed individuals.Competing interests
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